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HIV Treatment Update for Prison and Jails: 2002
Anne De Groot, M.D.*, Brown Medical School and Rick Altice, M.D.**, Yale HIV in Prisons Program

Safe Steering and the
Global AIDS Crisis
Bill Gates, founder of Microsoft, opened the 9th
Conference on Retroviruses and Opportunistic
Infections (9th CROI) as keynote speaker by
comparing the AIDS epidemic in Africa to the
sinking of the Titanic. This analogy is extremely
apt, for not only is it proving difficult to gauge the
severity of the epidemic by examining the tips of
the icebergs (those known to be infected), but it
also appears that the number of lifeboats on
board (available treatments) is inadequate to
ensure the safety of all the passengers.
Although Bill Gates did not elaborate further, he
clearly implied that passengers in steerage may
not be aware of existing disparities between their
chances of survival compared to passengers
holding a higher class of ticket. He invoked philanthropy as one potential solution to the global
AIDS crisis, and asked every conference participant to view those afflicted by HIV/AIDS as their
neighbors in the world village and to engage in
the battle against AIDS on pure humanitarian
grounds.
This article will review aspects of the 9th CROI
relevant to the management of HIV and hepatitis
in correctional settings. The impact of research
reported at the CROI on the current management of HIV infection, as summarized in HHS
guidelines (last updated Feb. 4, 2002), will also
be presented.

Starting Controversy
In only a few short years, recommendations on
initial antiretroviral treatment in the treatmentnaïve individual have completely changed
course. In 1996, the "hit early, hit hard" approach
to HIV management was unveiled by David Ho
and colleagues at the World AIDS conference in
Vancouver. Their recommendation for early,
intense therapy was based on the results of
mathematical models that predicted that HIV
infection could be eradicated from infected cells
in a matter of years if viral replication were completely suppressed.1 Unfortunately, these early
models of HIV replication were flawed because it
was not known at the time that HIV could persist
for decades in resting T cells, macrophages, and
other "sanctuary" sites. It is now recognized that
this persistent virus is a source for renewed viral
replication and infection of other cells when
HAART is discontinued.2
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Gradually, optimistic sessions on "HIV
Eradication" at the annual CROI meeting have
given way to sessions focusing on optimizing the
durability of therapeutic response and limiting
drug toxicity using strategic treatment interruption (STI), immunotherapy, and other strategies
which reduce exposure to or even obviate the
need for antiretroviral therapy.3 This year, initial
hopes for interrupted therapy were dashed as
STI was put to "R.I.P." (rest in peace) by Bernard
Hirschel, who summarized data from the Swiss
Spanish Intermittent Therapy Trial (SSITT).4
Reports on the long term side effects associated
with HAART also became more numerous
(Adverse Events will be covered in Update Part
Two in the June/July issue of HEPP News;
Volume 5, Issue 6/7).
In the "Controversies" session of the CROI conference, Richard Chaisson, M.D., of Johns
Hopkins University raised another note of caution and proposed that we temper our enthusiasm for early treatment by considering the
potential for treatment-related adverse events
along with new data on patient outcomes when
deciding when to initiate treatment.5 This more
cautious approach to the initiation of HAART is
also reflected in the most recent version of the
HHS Guidelines for the management of HIV
infection in Adults and Adolescents6 (Table 1):
"While randomized clinical trials provide strong
evidence for treating patients with <200 CD4+ T
cells/mm3, the optimal time to initiate antiretroviral therapy among asymptomatic patients with
CD4+ T cell counts >200 cells/mm3 is not
known. For individuals with >200 CD4+ T
cells/mm3, the strength of the recommendation
for therapy must balance the readiness of the
patient for treatment, consideration of the prognosis for disease-free survival as determined by
baseline CD4+ T cell count and viral load levels,
and assessment of the risks and potential
benefits associated with initiating antiretroviral
therapy." 6
Continued on page 2
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Table 1: Indications for Initiating HAART in HIV-1 Infected Patients

(continued from page 1)

An important new concept that was discussed at the meeting was the "AUC" or
"area under the curve" for HIV viral load.
There appears to be a good correlation, as
expected, between viral load AUC and clinical outcomes. It should come as no surprise that lower viral load AUC (fewer
detectable viral loads or lower viral loads
measured at several time points during
therapy) were directly correlated with
patient adherence and combination therapy potency. This relationship between
adherence and outcomes is emphasized in
the HHS guidelines: "patient readiness" is
to be used as a key determinant for initiating therapy.6

Starting at <200 CD4
Due in part to the ability of HAART to lower
viral loads for prolonged periods of time,
new data from longitudinal cohort studies
appears to demonstrate that delaying
HAART may not be detrimental in the context of the current standard of HIV care in
developed countries (in Europe, the US or
Australia, where the cohort studies were
located). One study by a group in Europe7
showed that virologic suppression can be
achieved even when starting HAART at
CD4+ T cell <200, and that the level of virologic suppression achieved was equivalent
to starting HAART at >350. At first glance,
this appeared to contrast with another
report by Sterling et al., which indicated
that starting HAART at higher CD4+ T cell
appeared to be associated with improved
clinical outcomes.8,9 However, Richard
Chaisson, one of the investigators, pointed
out that even in this study, the beneficial
effects of early treatment were eliminated
when controlling for the viral load AUC.5,8 In
other words, patients who achieved similarly low viral loads did equally well whether
they were started at <200 or <350.8 Dr.
Chaisson was emphatic, stating "Patients
started on antiretroviral therapy with CD4+
T cell counts >350 are likely to experience
considerable toxicity as well as emergence
of drug-resistant virus in the absence of a
compelling clinical benefit. Initiation of therapy should be based on CD4+ T cell count
and the patient's ability to comply with complex and potentially toxic regimens." 5

Starting at >350 CD4
In contrast, several clinical studies presented at the 9th CROI appeared to
demonstrate that earlier HAART initiation
(at CD4+ T cells >350) might be advantageous. David Cooper, from the Sydney
(Australia) AIDS group10 showed that
immune function could be restored in
patients who started HAART later, but the
durability of the restoration might be
decreased. In that study, as in the
EUROSIDA study, baseline CD4+ T cell

Clinical
Category

CD4+ T Cell
Count

Plasma HIV
RNA

Recommendation

Symptomatic
(AIDS, severe
symptoms)

Any value

Any value

Treat

Asymptomatic,
AIDS

<200/mm3

Any value

Treat

Asymptomatic

>200/mm3 but
<350 mm3

Any value

Treatment should generally be offered,
though controversy exists.^

Asymptomatic

>350/mm3

>55,000
(by bDNA or
RT-PCR)

Some experts would recommend initiating therapy, recognizing that the 3-year
risk of developing AIDS in untreated
patients is >30% and some would defer
therapy and monitor CD4+ T cell
counts more frequently.

Asymptomatic

>350/mm3

<55,000
(by bDNA or
RT-PCR)

Many experts would defer therapy and
observe, recognizing that the 3-year
risk of developing AIDS in untreated
patients is 15%.

^Clinical benefit has been demonstrated in controlled trials only for patients with CD4+ T cells
<200/mm3. However, most experts would offer therapy at a CD4+ T cell threshold <350/mm3. A
recent evaluation of data from the MACS cohort of 231 individuals with CD4+ T cell counts >200
and <350 cells/mm3 demonstrated that of 40 (17%) individuals with plasma HIV RNA <10,000
copies/ml, none progressed to AIDS by 3 years (Alvaro Munoz, personal communication). Of 28
individuals (29%) with plasma viremia of 10,000-20,000 copies/mL, 4% and 11% progressed to
AIDS at 2 and 3 years respectively. Plasma HIV RNA was calculated as RT-PCR values from
measured bDNA values. For further information, see the full HHS guidelines.
Adapted from HHS guidelines, updated February 4, 2002, p.376

count at initiation of therapy determined
which patients would achieve CD4+ T cell
counts above 500 cells/mm3 with HAART.11
Another study by the Hopkins group
(Palella et al.) showed that initiation of
HAART at CD4+ T cell 201-350/mm3 was
associated with reduction in mortality in
comparison with patients for whom HAART
was delayed until they reached a lower
CD4+ T cell count.12 Thus, individual clinicians will need to continue to use their discretion when considering when to start
therapy. Perhaps all of these studies are
best interpreted as indicating that patients
who are highly motivated (and expected to
achieve lower viral load AUC) might
choose to initiate therapy at lower CD4+ T
cell counts (<200) and still achieve excellent virologic response. Delaying therapy
may have other important effects on the
overall epidemic: (1) HIV is more easily
transmitted by persons who are HIV infected and not on treatment and (2) delayed
treatment may impair the reconstitution of
anti-HIV immune responses - which may
become more important as therapeutic HIV
vaccines advance to Phase III trials. The
bottom line is that the whole patient (medical status, psychosocial context, motivation, etc.) must be considered.
Despite these revisions to the guidelines,
not all HIV treaters are convinced that
delayed treatment is the optimal strategy.
As Brigitte Autran (Pitié-Salpétrière, Paris,
France) explained in her opening day ple-

nary talk, HIV immunopathogenesis data
seems to indicate that starting HAART earlier may preserve T cell responses that are
specifically directed against HIV, which are
associated with better control of chronic
infection.13 In her plenary talk on immune
restoration, Autran postulates that the early
recovery of anti-opportunistic infection (OI)
CD4+ T cell response is due to the presence of chronic OI. She provided data
showing that Tetanus, CMV, and Candida
responses return after HAART, but not with
anti HIV-specific help: the CD4+ T cells
specific for HIV that had been erased soon
after primary infection do not reconstitute,
while the preexisting CD8+ T cells
decrease in direct proportion with the viral
load.13 Such data, as well as information
presented at the 9th CROI on once-a-day
regimens and 2nd generation ART drugs
with fewer side effects, may eventually reshift treatment recommendations towards
earlier (>350 CD4+ T cells/mm3) treatment
in the future.

Impact of Clinical Care
In what now appears to be an annual
update on the impact of access to specialty care in HIV morbidity and mortality,
Kitahata and colleagues reported that the
risk of HIV disease progression and death
was determined by whether or not patients
received HAART within 12 months of their
initial clinic visit (this study cohort consisted
of 238 patients receiving care at a university-affiliated HIV clinic). CD4+ T cell counts
Continued on page 4
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Letter from the Editor
Dear Colleagues:
The two themes that run through this issue of HEPP News are the changing standards of HIV
care and women's issues.
Most of us are wary of changes of any sort because change may result in confusion, suspicion, and extra work. With regard to HIV care, the standard for initiating antiretroviral therapy
in asymptomatic individuals has changed from relatively early intervention (CD4 count < 500
cells per cc of blood or viral load greater than 20,000 copies per cc of blood) to delayed therapy (CD4 < 350 cells/cc and VL > 55,000). The main article provides a summary of the latest
HIV research that was presented at the 9th Conference on Retroviruses and Opportunistic
Infections (February 24 - 28, 2002, Seattle, Washington) and also highlights the changes in the
HHS treatment guidelines. The results of clinical trials and other research provide us, the clinicians, with the evidence upon which to base our medical treatment. Within the prison, adherence to these new guidelines will probably result in fewer patients on antiretroviral therapy.
While this may please administrators who oversee the budget for medical care, it may also
arouse suspicion in inmates who suspect we are skimping on their care. So clinicians will have
to work extra hard to educate themselves and their patients about the pros and cons of early
versus delayed therapy. Testing in correctional settings also continues to be a high priority,
given the large number of people who do not know they are infected. You can expect to see
more changes in future guidelines as the latest research results are incorporated into evidence-based medicine, the most rational way of treating medical conditions.
Because Mother's Day occurs in May, HEPP News has, according to our tradition, included a
spotlight on women and HIV. Unfortunately, as this spotlight indicates, there is still a relative
dearth of research on women's issues. Nonetheless some encouraging information has been
reported: low-grade cervical lesions in HIV-positive women may have a lower than expected
frequency of progression to neoplasia and mother-to-child transmission of HIV can almost be
eliminated if the mother receives antiretroviral therapy to reduce the VL to undetectable levels.
After reading this issue, providers should understand the changes in the HHS guidelines, be
familiar with the Black Box Warnings and the new research on women and HIV, and have an
idea of how to treat the HIV/HCV coinfected patient.
We hope you enjoy this issue of HEPP NEWS. Please provide us with your feedback and comments so that we can continue to provide you with useful information for treating incarcerated
patients with HIV and/or HCV.
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HIV Treatment Update...
(continued from page 2)

were also an independent risk factor for disease progression. Patients with CD4+ T cell
counts < 200 cells/mm3 were at significantly
greater risk of disease progression than
patients with higher CD4+ T cell counts,
even if antiretroviral therapy was started.
These data again suggest that starting therapy sooner rather than later may be beneficial regardless of the CD4+ T cell count.14

Adverse Effect
Accumulation
Part of the dampening of enthusiasm for
early treatment at the 9th CROI is due to
accumulation of data on adverse events
associated with HAART. The list of adverse
events associated with HAART now
includes: lactic acidosis/ hepatic steatosis,
HAART-associated hepatotoxicity, fat maldistribution or lipodystrophy, hyperlipidemia,
osteopenia, skin rash, and new additions to
the HHS guidelines: hyperglycemia,
osteonecrosis, and osteoporosis. And, as
shown in the HIV 101, the list of serious side
effects (issued as "black box" warnings by
the FDA) is growing, with the recent addition
of NNRTI-associated hepatitis (nevirapine)
and NRTI-associated lactic acidosis in association with Guillain-Barré- like neurotoxicity
following severe lactic acidosis (as reported
at the 9th CROI). Skin rash has now become
a class-related adverse event (associated
with NNRTIs).

Emerging Resistance
Reports at the 9th CROI also raised concern
about the impact of drug resistance on future
HAART therapy. This concern is reflected in
the new emphasis in the HHS guidelines on
genotyping at initiation of HAART for individuals in whom acute HIV infection is diagnosed. For example, Bennett and colleagues studied 923 recently diagnosed
people in 10 US cities (1998-2000) and
noted that resistance to 1 or more antiretroviral from any class increased from 3.8% to
9.0% during the study period.15 Grant and
colleagues evaluated viral genotypes in 225
recently infected individuals in San
Francisco, California and found that resistance to any class of drug increased from
16.7% to 27.6% between July 1996 and
2001.16 In contrast, investigators in Sydney,
Australia, failed to observe such an
increase.17 The new HHS guidelines reflect
concerns about the impact of drug resistance on response to initiation of treatment:
"Transmission of drug-resistant strains of
HIV has been documented, and may be
associated with a suboptimal virologic
response to initial antiretroviral therapy. If
the decision is made to initiate therapy in a
individual with acute HIV infection, optimization of the initial antiretroviral regimen
through the use of resistance testing is a
reasonable, albeit untested, strategy.

4

Because of its more rapid turnaround time,
the use of a genotypic assay may be preferred in this setting." 6

evolution. These data have important implications for natural history and vaccine development.18

Interrupted therapy and
Immunity

Stopping Therapy

As is well known, in the course of chronic
infection, HIV specific T cells are extremely
activated and active, located in proximity to
dendritic cells (DCs) that not only present
HIV specific epitopes (which activate them)
but also have live virions on their surface.
Therefore the DCs simultaneously activate
and infect CD4+ T helper cells - which then,
in turn, become the target of HIV-specific
CD8+ cytotoxic T cells (CTL). This leads to
the preferential depletion of CD4+ T cells
specific for HIV, as has been described by a
number of expert HIV immunologists including B. Autran and Bruce Walker. The
process is termed "depletion of HIV-specific
T helper cells" and is a critical issue at the
heart of controversies related to initiation of
HAART, STI, and therapeutic vaccination.
What happens to the HIV specific CD4+ T
cells? After interruption of HAART (as with
STI), Autran, speaking in the plenary session, saw increases in HIV specific CD4+ T
cells that were associated with the rebound
in viremia. The CD4+ T cells rebounded
even before the virus was detectable, and,
alarmingly, usually disappear before the
treatment was re-introduced. She postulated
that these HIV-specific CD4+ T cells are
immediately eliminated (either by HIV-specific CD8+ T cells or by the direct destruction
of the cell due to viral replication). Thus,
Autran says that STI may actually be problematic - because as each wave of CD4+ T
cells is re-introduced, they are wiped out by
the HIV-specific CD8+ T cells. This observation has major implications for patients who
undergo periods of "Unstructured Treatment
Interruption" such as those individuals who
cycle through correctional facilities.
Furthermore, given this information, STI is
bound to fail.
A related report at the 9th CROI demonstrated the co-evolution of antibody responses and viral escape, in waves, during infection. Using a novel HIV entry assay,
Richman and colleagues evaluated the coevolution of HIV envelope and neutralizing
antibody from plasma following primary HIV1 infection. Most patients (12/14) rapidly
generated strong neutralizing antibody
responses to autologous virus. However,
each sequentially replicating generation of
viruses consistently and rapidly escaped the
concurrent neutralizing antibody response
by developing mutations in the RNA
sequences that code for the neutralizing epitopes. The rate of viral neutralization escape
was remarkable and indicated that neutralizing antibody can exert a previously unappreciated level of selective pressure on viral

In a report from CROI that was very relevant
to HIV care in corrections, the EUROSIDA
group evaluated the impact of stopping antiretroviral therapy. They evaluated the clinical outcome of 565 patients in the EUROSIDA study who interrupted HAART on their
own. Of the 565, 49% have restarted therapy, and 290 developed a new AIDS Related
Event (ARE) or died. Twenty-eight of these
events occurred after being off therapy for at
least 3 months (28/140 person-years = 0.20
per person-year). The relative hazard of a
new ARE or death associated with having
been off therapy for at least 3 months was
2.4 (95% CI 1.6-3.6; p=0.0001) after adjustment for the latest CD4+ T cell count and
viral load. These data indicate that risk of
AIDS and death increases more than two
fold upon therapy interruption or stopping.
The absolute risk remains closely linked to
the latest CD4+ T cell count and was highest
among patients with a latest CD4+ T cell
count below 200/mm3.19

Detecting HIV
Perhaps the most important role that corrections plays in the global AIDS crisis is the
role of testing and educating HIV-infected
individuals. At the 9th CROI, Fleming and
colleagues from the Centers for Disease
Control and Prevention (CDC) reported on
the continued spread of HIV in the United
States. They estimated that in 2000,
between 850,000 and 900,000 people in the
United States were living with HIV infection,
and 40,800 people acquired infection. A
substantial number of people with HIV infection (between 180,000 and 280,000) are
unaware of this fact, further increasing the
risk for transmission.20
Perhaps more importantly, it is still clear that
many HIV-infected subjects do not know
their status. The goal of the CDC's Project
SAFE (Serostatus Approach to Fighting the
Epidemic) is to bring people into care and
counseling earlier.21 Unfortunately, it now
appears that treatment of HIV-infected individuals is to be delayed until they achieve
lower CD4+ T cell counts, leading to the
inevitable question from the patient: Why get
tested? Clearly, because there are so many
individuals who are unaware of their infection, it is important to continue to test individuals for HIV. This is particularly true in
corrections, a setting with which many people at high risk for HIV infection come into
contact. While the patient may not see the
benefit of getting tested for HIV, the correctional health care provider must continue to
encourage testing of individuals at risk for
infection. Returning to the image of the
Titanic proposed by Bill Gates, reports preContinued on page 5
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HEPPigram
Correctional Physicians Dilemma:
Which to Treat First in the Co-infected (HIV/HCV) Patient?

Prioritize HIV treatment if . . .

w HIV is advanced

Prioritize HCV treatment if . . .

w Early HIV infection, treatment
not needed yet

w HCV is stable
w EtOH/drug use still an issue
(must be totally controlled first)
w Controlling HIV may lower
HCV VL and improve
immune response to HCV

w HCV more advanced
w Increased liver damage on
biopsy
w HCV infection complicating
HIV treatment

References: Bonacini, M. AIDS Reader. 2002;12(1):19-26./ AIDS Clinical Care. 2002 May; 14 (5):39-43./ HEPP News, April 2002.

HIV Treatment Update...
(continued from page 4)

sented at the 9th CROI leave us lost at sea, surrounded by dangers
that are half-perceived. The best advice for correctional health care
providers may be to stay tuned in for more changes in course as our
understanding of HIV continues to evolve.
DISCLOSURES:
*Consultant & Speaker's Bureau: Abbott, Agouron Pharmaceuticals,
Merck, Roche, Boehringer-Ingelheim, Schering Plough
**Consultant and Speaker's Bureau: Abbott Laboratories, Boehringer
Ingelheim, Roche, Agouron, Bristol Myers Squibb, GlaxoSmithKline,
Gilead Sciences, Ortho Biotech and Merck Pharmaceuticals.
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Spotlight: An Update on HIV Care for Women
by Rick Altice, M.D.*, Yale HIV in Prisons Program
The topic of HIV management in women received hardly any attention at the 9th CROI, despite recent findings on the gender differences in CD4+ T cell counts and viral loads at the time of AIDS
diagnosis (Table 1). The significance of these differences remains
to be determined. Overall, the women appear to progress to AIDS
at the same rate as men, given equivalent access to care1, and the
CD4 T cell counts are more similar than they are different2. Until
large cohort comparisons are performed, it is not clear whether we
should be starting women on treatment using different viral load
thresholds or T cell measurements than are used for men.
Despite the relative lack of focus on women's issues, a few important insights on the management of HIV+ women emerged. As
presented in one late breaker session that has relevance to the
management of HIV infection in incarcerated women3, HIV
seropositive and HIV seronegative women with biopsy-proven
Squamous Intraepithelial Lesions (SIL) of the cervix were randomized to two distinct interventions, based on whether they had low
(LGSIL) or high (HGSIL) grade cervical lesions. Women with
LGSIL were randomized into observation or cryotherapy; those
with HGSIL received either cryotherapy, LEEP or surgical cone
therapy. At one year, HIV seropositives with LGSIL were less likely to have a normal pap smear than HIV seronegatives (24% vs.
61% for those being observed without intervention and 56% vs.
95% among those having received cryotherapy). Only 4% of HIV
seropositive women with LGSIL who were either observed or who
received cryotherapy developed HGSIL at one year. Among HIV
seropositives with severe cervical disease (HGSIL), all treatment
modalities resulted in a much poorer response rate than for HIV
seronegatives. The proportion with a normal pap smear was 29%,
42% and 45% for those receiving cryotherapy, LEEP or cone treatment, respectively (these differences were not statistically significant). Thus, no single treatment modality was preferred.
The take home message for correctional providers is that HIV
seropositive women with SIL do not respond to standard cervical
therapies as well as HIV seronegatives. However, those HIV
seropositive women with LGSIL may not need immediate interventions as was once thought because the rate of progression is
not fast. Among HIV seropositive women with HGSIL, therapy is
indicated; however there does not appear to be any preferred
treatment modality. Correctional providers should also recognize
that if treatment is delayed and the patient leaves the correctional
facility, the careful follow-up available in the correctional system
may be lost and the disease may progress without further care,
resulting in increased morbidity and mortality in the community.
Until data points to the contrary, Pap smear abnormalities should
continue to be followed up and treated in a timely fashion.
Mother-to-child transmission (MTCT) of HIV was another topic pertinent to both women and children that was reviewed at the 9th
CROI. Judith Currier4 summarized recent findings from PACTG
(Pediatric AIDS Clinical Trials Group) 316 (use of single-dose nevirapine to mother and infant in addition to other maternal antiretrovirals during pregnancy)5 which demonstrated that it is possible to
reduce MTCT rates from the 8% observed in the famous 076 study
(AZT monotherapy) to 1.6% with the use of potent combination

Table 1: Differences Between Men and Women in
HIV Disease
CD4 Count
at AIDS

CD4 Count
at Death

Baseline
RNA
(b-DNA)

Follow-Up
RNA
(RT-PCR)

Women

146

44

3365

45,416

Men

49

22

8907

93,130

antiretroviral therapy. Lower viral loads had a dramatic effect on
the transmission of HIV: among women with HIV-1 RNA <1000
copies/mL throughout pregnancy, transmission rates were 1.8%
with a single antiretroviral agent and 0.8% when multiple agents
were used. In addition, for women whose last measure of virus
load during pregnancy was <1000 copies/mL, transmission rates
were <1%.6
Data were presented from 2,087 pregnancies of HIV-infected
women since January 1998 in a review of PACTG 367. Given
excellent care (97% received prenatal care, and 60% were on protease inhibitors) there were no significant differences between
vaginal delivery and elective C-section delivery; however, when
only intrapartum transmissions were considered, the transmission
rates during vaginal deliveries and elective C-sections were 3.4%
and 1.7%, respectively, a difference that approached statistical significance.
Due to concern about serious adverse events related to lactic acidosis, warnings on the use of d4T and ddI during pregnancy have
been issued (FDA, package inserts). According to one report
(AERS), 8 pregnant women developed pancreatitis and/or lactic
acidosis at 32 weeks gestation. In 7/8 (88%) cases, the patient was
taking the combination of ddI and d4T. The eighth patient was taking d4T and 3TC. Among the 7 women taking ddI and d4T, 3 died.
Fetal death was documented in 3 of these cases, including the
woman taking d4T and 3TC. These resesarchers found that the
combination use of d4T and ddI during pregnancy increased the
risk of development of lactic acidosis and/or pancreatitis, that the
risk appears to be greatest in the third trimester and with longer
duration of ddI/d4T therapy. Based on these findings, ddI/d4T therapy should be given only to those pregnant women in whom the
potential benefits clearly outweigh the risks.7
DISCLOSURES:
*Consultant and Speaker's Bureau: Abbott Laboratories, Boehringer
Ingelheim, Roche, Agouron, Bristol Myers Squibb, GlaxoSmithKline,
Gilead Sciences, Ortho Biotech and Merck Pharmaceuticals.
REFERENCES:
1. Chaisson RE, Keruly JC, Moore RD. N Eng J Med. 1995
Sep 21;333(12):751-6.
2. Lyles. JID 1999;180:1018.
3. Abstract LB16, 9th CROI, February 24-28, 2002. Seattle, Washington.
4. Currier JS. Abstract S19. 9th CROI.
5. Dorenbaum A. For the PACTG 316 Study Team. Abstract LB7.
9th CROI.
6. Shapiro D, Tuomala R, et al. PACTG 367. Abstract 114. 9th CROI.
7. Marcus K, Truffa M, et al. Abstract LB14. 9th CROI.

Correction: In the April 2002 issue of HEPP News, in the section titled "HIV/HCV Response to Therapy," there are references to studies
demonstrating the efficacy of pegylated interferon/ribavirin combination therapy in coinfected patients. The pegylated interferon used in
these studies was pegylated interferon alfa 2a (Pegasys, Roche), NOT the pegylated interferon alfa 2b (PEG-Intron, Schering) that had
been discussed earlier in the article. Furthermore, in the HIV101, it was not made clear that dosing ribavirin by weight, used with standard interferons, has not been FDA approved for use with pegylated interferon alfa 2b (PEG-Intron), although some experts believe that
the data can be extrapolated. This is based on a retrospective analysis of a study in which some lighter weight patients received only
800 mg ribavirin. PEG-intron is currently only FDA approved for use with 800 mg daily ribavirin.
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"Black Box Warnings" For Antiretroviral Medications
Certain medications are associated with adverse events. Those adverse events that may lead to death or serious injury are often
required (by the FDA) to be placed in a prominent box, known as the "black box" on the product insert. Presented here are antiretroviral medications along with their "black box warnings". Note that there may be other toxicities associated with these medications that are listed in the current HHS guidelines, available at http://www.hivatis.org/guidelines/adult/Feb04_02/AdultGdl.pdf.

Antiretroviral Drug

Black Box Warnings

Generic Name (Abbr., Brand name, Mfr.)
NRTIs (Nucleoside Reverse Transcriptase Inhibitors)
Abacavir (ABC, Ziagen,
GlaxoSmithKline [GSK]) or as Trizivir**
See HEPP News January 2002,
HEPPigram, p. 5

Ø Fatal hypersensitivity reactions:
w Signs/Symptoms: fever, skin rash, fatigue, GI and respiratory symptoms
w ABC should be discontinued as soon as hypersensitivity is suspected
w ABC SHOULD NOT be restarted; If restarted, more severe symptoms will recur
within hours and may include life-threatening hypotension and death
w ABC sensitivity syndrome should be noted on the patient's chart
Note that Trizivir contains ABC and sensitivity to Trizivir should be noted as well
Ø Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have
been reported with the use of antiretroviral nucleoside analogues alone or in combination

Didanosine (ddI, Videx, Videx-EC,
Bristol Myers-Squibb [BMS])

Ø Fatal and nonfatal pancreatitis have occurred with ddI alone or in combination with
other antiretroviral agents
w ddI should be held if pancreatitis is suspected and should be discontinued if
pancreatitis is confirmed
Ø See fatal lactic acidosis above (in abacavir box)
Ø Fatal lactic acidosis has been reported in pregnant women who received a combination of ddI and d4T along with other antiretroviral combinations, therefore, ddI and d4T
combination should only be used during pregnancy if the potential benefits clearly outweigh the potential risks

Lamivudine (3TC, Epivir, GSK) or as
Combivir* or Trizivir**

Ø See lactic acidosis above (in abacavir box)

Stavudine (d4T, Zerit, BMS)

Ø See lactic acidosis above (in abacavir box)
Ø See fatal lactic acidosis above (in didanosine box)
Ø Fatal and non-fatal pancreatitis have occurred when d4T was part of a combination
regimen with ddI with or without hydroxyurea
Ø Potentially fatal neuromuscular reaction mimicking Guillain-Barre syndrome has been
reported

Zidovudine (AZT, Retrovir, GSK) or as
Combivir* or Trizivir**

Ø AZT may be associated with hematologic toxicities, inluding granulocytopenia and
severe anemia, particularly in advanced HIV patients
Ø Prolonged AZT use has been associated with symptomatic myopathy
Ø See lactic acidosis above (in abacavir box)

Nucleotide Reverse Transcriptase Inhibitor
Tenofovir (TDF, Viread, Gilead)

Ø See lactic acidosis above (in abacavir box)

NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
Nevirapine (NVP, Viramune,
Boehringer-Ingelheim)

Ø Severe, life-threatening hepatotoxicity, including fulminant and cholestatic hepatitis,
hepatic necrosis, and hepatic failure. Patients should be advised to seek medical evaluation immediately should signs and symptoms of hepatitis occur.
Ø Severe, life-threatening, and even fatal skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash,
constitutional findings, and organ dysfunction have occurred with NVP treatment
Ø Patients should be monitored intensively during the first 12 weeks of NVP therapy to
detect potentially life-threatening hepatotoxicity or skin reactions.
Ø A 14-day lead-in period with NVP 200mg daily must be strictly followed.
Ø NVP should not be restarted after severe hepatic, skin, or hypersensitivity reactions

PIs (Protease Inhibitors)
Amprenavir Oral Solution (APV,
Agenerase, GSK)

Ø Because of potential risk of toxicity from large amounts of the excipient propylene glycol in APV Oral Solution, it is contraindicated in: children < 4 years old; pregnant women;
patients with renal or hepatic failure; patients treated with disulfiram or metronidazole
Ø Oral solution should be used only when APV capsules or other PIs cannot be used

Ritonavir (RTV, Norvir, Abbott
Laboratories)

Ø Co-administration of RTV with certain medications may result in potentially serious
and/or life-threatening adverse events due to effects of RTV on hepatic metabolism of
certain drugs

Special note: Providers need to note the following combination therapies as dangerous reactions that apply to any of the drugs in the combination form
apply to the combination therapy as well: * Combivir, GSK = Lamivudine + Zidovudine; ** Trizivir, GSK = Lamivudine + Zidovudine + Abacavir
The following antiretrovirals have no "black box warnings" (see guidelines for full information on other toxicities): Delavirdine (Resciptor, Pharmacia &
Upjohn); Efavirenz (Sustiva, BMS); Indinavir (Crixivan, Merck & Co.); Lopinavir/Ritonavir (Kaletra, Abbott Labs); Nelfinavor (Viracept, Agouron);
Saquinavir (Invirase, Fortovase, Hoffman-LaRoche).
Adapted from: HHS Adult and Adolescent Guidelines, Table 16 (p.49-50).
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Save the
Dates
Sixth Annual HIV Update:
Contemporary Issues in
Management
June 6-8, 2002
Boston, Massachusetts
Fee: After April 26: $595, $375
Residents and Fellows
Call: 617.384.8600
Fax: 617.284.8686
Email: hmscme@hms.harvard.edu
Continuing ed. credit available
Management of Hepatitis C:
2002
June 10-12, 2002
Bethesda, Maryland
Sponsored by the National
Institutes of Health (NIH)
Fee: None
Visit: http://consensus.nih.gov
Conference can be viewed via the
Internet at http://videocast.nih.gov
Call: 301.592.3320
Fax: 301.593.9433
Email: hepc@prospectassoc.com
10th National Roundtable for
Women in Prison
June 20-23, 2002
New York, New York
Fee: After May 15: $175
Visit: www.wpaonline.org
Email: rnelson@wpaonline.org or
tkingsley@wpaonline.org
XIV International AIDS
Conference
July 7-12, 2002
Barcelona, Spain
Fee: After May 1: $1050 (special
rates and scholarships available)
Visit: www.aids2002.com
Email: aids2002.registration@
congrex.se
6th Annual United States
Conference on AIDS (USCA)
September 19-22, 2002
Anaheim, California
Fee: Before June 14th $330 members/
$400 non-members;
before August 23- $375/$450
Visit: www.nmac.org/usca2002/
Call: Paul Woods,
202.483.6622 ext. 343
Email: pwoods@nmac.org
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Inside News
HCV
New Data Shows High SVR For Genotype 1
Patients on Pegylated Interferon (Pegasys)
hivandhepatitis.com, 4/18/02, www.easl.ch
At the European Association for the Study of the
Liver (EASL) meeting in April, Roche presented
data from prospective trials with its new pegylated interferon, Pegasys. Overall (including results
from all HCV genotypes), the data showed a
sustained virologic response (SVR; see HEPP
News, April 2002) rate of 61%; for patients with
genotype 1 HCV, (the most common and the
hardest to treat) the SVR rate was 51%, the
highest SVR for genotype 1 patients seen thus
far. These patients received 180 micrograms of
Pegasys once per week along with 1000mg (if
<75kg) or 1200mg (if >75 kg) of ribavirin per day
for 48 weeks. Patients with genotype 2 or 3 who
received 180mg of Pegasys once per week
along with the lower 800 mg of ribavirin for 24
weeks achieved an SVR of 78%. Roche expects
FDA approval of Pegasys later this year.

HIV
Tenofovir Increases DDI Levels in Blood
Bristol-Meyers Squibb Letter to Health Care
Professionals, 5/02
A new study on the pharmacokinetics of ddI
(Videx, BMS) and tenofovir (Viread, Gilead) has
shown that administration of ddI, in the extended
formulation or in the capsular form, one hour
before tenofovir DF 300 mg QD (both in the fasting state) results in roughly a 40% increase in
didanosine exposure relative to the administration of ddI (EC or tablets) 400 mg alone in the
fasted state. Furthermore, if the two drugs are
co-administered with a light meal, there is an
even greater (50 to 60% increase in ddI exposure, tablet and EC, respectively) relative to ddI
given alone in the fasting state. The impact of
this increase is not clear, but ddI side effects may
become more pronounced when ddI is used with
tenofovir. Providers are encouraged to monitor
patients taking standard doses of ddI and tenofovir for adverse events related to these drugs
(see HIV101 for Black Box Warnings).
Mandatory Testing Before Release?
Miami Herald, 4/23/02
A bill passed by the Florida State legislature and
senate would make HIV testing mandatory for all

inmates 60 days prior to release. According to
the legislation, inmates who test positive for HIV
will be provided with a 30-day supply of medications upon release. Some corrections experts
believe the legislature has not truly comprehended the price tag for this proposed legislation, as
the legislature appropriated slightly more than
half of the funds the Department of Corrections
requested to cover the cost of the program.
HIV Seroprevalence of New York State DOC
Inmates Drops Over the Past 12 Years
Abstract 767-W, 9th CROI
A study examining HIV infection in New York
State correctional facilities found that the seroprevalence among female inmates dropped from
18.8% in 1988 to 13.9% in 2000. Among male
inmates, the HIV seroprevalence dropped from
17.6% to 4.7% in the same time period. Injection
drug use also decreased from 1988 to 2000,
dropping from about 28% for both male and
female inmates to 5.8% for male inmates and
14.5% for female inmates. Experts recommend
that more prevention services be offered to
parolees and jail inmates.
Valganciclovir Effective as Induction Therapy
for CMV
NEJM 2002; 346 (15): 1119-1126.
A new study has shown that oral valganciclovir
(Valcyte, Roche) is as effective in induction therapy for cytomegalovirus (CMV) as the intravenous
ganciclovir
traditionally
used.
Valganciclovir, in its oral form, is more convenient for most patients than an intravenous drug.

TB
HEPP TB Article: CDC Communication
According to the CDC, total numbers of TB
cases in the United States have declined 39%
since 1992. The decline of TB in corrections has
been even greater: there were 588 cases of TB
in corrections in 2000, compared with 1065
cases in 1994, a decline of 45%. Furthermore,
the case rate of TB in corrections stated on p.2
of the March 2002 issue of HEPP may be overstated as the "% of Population Incarcerated" in
Table 1 (p.1) did not take into account those persons incarcerated in local and county facilities,
thereby understating the percent of the state
population that is incarcerated.

Resources & Websites
9th Annual Conferences on Retroviruses and
Opportunistic Infections
http://www.retroconference.org/2002/

the correctional industry, listen or read at
http://www.americanradioworks.org/features/
corrections/index.html

New Bureau of Justice Statistics Report: Prison
and Jail Inmates at Midyear 2001
http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim01.pdf

amfAR HIV/AIDS Treatment Directory,
2002 Winter Edition
Free (incl. shipping); Large quantities available
for clinic settings.
Contact Gretchen.Schmelz@amfar.org or
call 212.806.1762

Correctional Health Care: Guidelines for the
Management of an Adequate Delivery System,
2001 Update
http://www.nicic.org/pubs/2001/017521.htm
Three Part Report: "Corrections, Inc."
American Radio Works report explores aspects of

Updated HHS Guidelines for the Use of
Antiretrovirals in Pregnant Women
http://www.hivatis.org/guidelines/perinatal/Feb4_02/
Perin.pdf
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through December 31, 2002.
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. For an HIV-positive, asymptomatic patient with a CD4+ T cell
count of 500 cells/mm3 and a viral load of 15,000 copies, what do
the majority of experts say should be done?
a) Treat the patient aggressively and immediately
b) Wait to treat the patient until the CD4+ T cell count falls below
400 cells/mm3, regardless of viral load
c) Defer therapy and observe the patient
d) Defer therapy until the patient is symptomatic
e) None of the above
2. Which of the following adverse events has been associated with
HAART?
a) lactic acidosis/hepatic steatosis
b) osteoporosis
c) skin rash
d) NNRTI-associated hepatitis
e) All of the above
3. The CDC estimates that between 20% and 30% of HIV-positive
people in the United States do not know they are infected.
a) True
b) False
4. "Lactic acidosis and sever hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral
nuceloside analogues alone or in combination." To which class(es)
of antiretroviral drugs does this statement apply?
a) NNRTIs
b) NRTIs
c) PIs
d) NRTIs and Nucleotide Reverse Transcriptase Inhibitors
e) NRTIs, NNRTIs, and PIs
5. New information presented at the 9th CROI discussed which of
the following findings related to SIL?
a) HIV-positive women with LGSIL were less likely to have a
normal Pap Smear than HIV-negatives at one year of follow-up
b) HIV seropositives with HGSIL had much poorer responses to
treatments than HIV seronegatives
c) No single treatment modality (i.e. cryotherapy, LEEP or cone
treatment) was preferred for HIV-seropositive women with
HGSIL
d) HIV-positive women do not respond to cervical therapies as
well as HIV-negative women
e) all of the above

6. A patient is coinfected with both HIV and HCV. A biopsy was
done and showed moderate cirrhosis of the liver. The patient’s
ALTs and LFTs are outside the normal range. The HIV has been
recently diagnosed, and the patient has a CD4+ T cell count of 500
cells/mL and a viral load of 35,000 copies/mL. Which infection
should the provider consider treating first?
a) HIV
b) HCV
c) treat both infections simultaneously
d) neither
e) begin HIV treatment first; when viral load is undetectable,
then begin treating the HCV
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